Meta Platforms
META
Tesla
TSLA
Alphabet-A
GOOGL
Alphabet-C
GOOG
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 3.960
- -0.050-1.25%
Close Dec 23 16:00 ET
- 3.960
- 0.0000.00%
Post 16:14 ET
252.67MMarket Cap-3.44P/E (TTM)
4.090High3.815Low748.07KVolume4.030Open4.010Pre Close2.95MTurnover2.37%Turnover RatioLossP/E (Static)63.81MShares13.68052wk High1.27P/B125.21MFloat Cap3.01052wk Low--Dividend TTM31.62MShs Float664.320Historical High--Div YieldTTM6.86%Amplitude1.530Historical Low3.946Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Larimar Therapeutics Stock Forum
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
Monday, 16th December at 7:00 am
• Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study
• Tissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells a...
Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics announced that the FDA has selected its therapy, nomlabofusp, for the START pilot program. This program aims to accelerate the development of treatments for rare diseases. Nomlabofusp is a novel protein replacement therapy targeting the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
The selection...
No comment yet